CorEvitas

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, CorEvitas sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 9 currently recruiting 4 completed top decile by trial count

CorEvitas: 13 sponsored US clinical trials, 9 recruiting.

CorEvitas sponsors 13 registered US clinical trials on ClinicalTrials.gov, 9 of them currently recruiting, and 4 completed. The most-studied condition in this pipeline is Alopecia Areata, with 2 trials.

Top-decile sponsor footprint

CorEvitas ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

13 total, page 1 of 1

RECRUITING

PPD™ CorEvitas™ Psoriasis (PSO) Early Treatment Response Non-Interventional Study

NCT07648602
RECRUITING

PPD™ CorEvitas™ Psoriasis (PSO) Rapid Response Non-Interventional Study

NCT07615712
RECRUITING

IBD Pregnancy Registry

NCT06910553
RECRUITING

CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry

NCT06804057
RECRUITING

RSV Vaccine Pregnancy Registry

NCT06521944
RECRUITING

CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry

NCT06562270
RECRUITING

CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry

NCT06238765
RECRUITING

CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry

NCT06100991
RECRUITING

CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry

NCT05745389
COMPLETED

PAtient-CenTric Chronic Pancreatitis Registry (PACT-CP)

NCT05762445
COMPLETED

Patient Outcomes: Real World Evidence in Rheumatoid Arthritis (POWER)

NCT04512573
COMPLETED NA

The CORRONA Treat to Target Trial: Outcomes and Feasibility in a US Population

NCT01407419
COMPLETED

Effectiveness Registry to Study Therapies for Arthritis and Inflammatory Conditions: The Corrona CERTAIN Sub-study

NCT01625650

Therapeutic Areas

Alopecia Areata 2
Respiratory Syncytial Virus (RSV) 1
Generalized Pustular Psoriasis 1
Systemic Lupus Erythematosus 1
Inflammatory Bowel Disease (IBD) 1
Atopic Dermatitis 1
Rheumatoid Arthritis 1

What is open in the CorEvitas pipeline

9 recruiting of 13 indexed (69% open); 4 completed (31%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Alopecia Areata (2 trials), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

CorEvitas: open-pipeline peers nationwide

Peers matched on 13 registered trials and 69% open enrollment, not the therapeutic-area sidebar.

CorEvitas sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 681012141618 0%20%40%60%80% Total trials Recruiting share CorEvitasAdaptimmuneAgennixAkili Interactive LabsAlumisRevolution MedicinesAnna Stanhewicz, PhDGlenn J. HannaSenthil Sadhasivam
CorEvitas sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

CorEvitas sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 69% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this CorEvitas page

13 registered trials is a research-attention snapshot, not an endorsement of CorEvitas or any single study.

  • 9 of CorEvitas's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Alopecia Areata is the condition CorEvitas studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Alopecia Areata trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

CorEvitas pipeline card: 13 registered trials from official public datasets.Report a data error.